Rein Therapeutics Inc.
RNTX
$1.27
$0.1412.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.53% | -239.15% | -299.71% | -125.97% | -44.28% |
| Total Depreciation and Amortization | -99.21% | -97.04% | -47.06% | 4.55% | -9.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,337.93% | 3,604.55% | 3,113.91% | 37.82% | -9.83% |
| Change in Net Operating Assets | 86.23% | 95.48% | 144.82% | 91.35% | 44.00% |
| Cash from Operations | 17.39% | -13.60% | -12.54% | -101.58% | -34.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -97.98% |
| Cash from Investing | -- | -- | -- | -100.46% | -98.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -82.01% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.26% | -- | -- | -- | -- |
| Cash from Financing | -85.30% | 17.49% | 12.81% | -- | -- |
| Foreign Exchange rate Adjustments | 98.39% | 100.00% | 100.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -285.37% | -208.92% | -136.91% | -22.78% | 57.97% |